Description
PrymaLab · Research use only
SLU-PP-332 (1000mcg) (30 Capsules)
Small-molecule ERR agonist, not a peptide: 30 capsules labelled 1000 mcg each
SLU-PP-332 is a synthetic agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, orphan nuclear receptors that govern much of a cell’s energy metabolism. It is a small aromatic molecule, not a peptide. This listing is a bottle of 30 hard gelatin capsules, each labelled 1000 mcg (1 mg) of SLU-PP-332 in a microcrystalline cellulose fill. The published work is preclinical: a 2023 discovery paper in cells and mice, read against a longer literature on what the ERRs do.
Specifications
| Property | Value |
|---|---|
| Compound | SLU-PP-332 (4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide; ERR agonist) |
| CAS number | 303760-60-3 |
| Molecular formula | C18H14N2O2 |
| Form | Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle |
| Storage, sealed | Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light |
| Safety data sheet | PL-SDS-152 |
What is in each capsule
Each capsule is labelled to contain 1000 mcg of SLU-PP-332, chemically 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide, mixed with microcrystalline cellulose inside a gelatin shell. The safety data sheet gives the amount and concentration as labelled and classifies the compound as a skin irritant (H315) and a serious eye irritant (H319). Neither the cellulose nor the shell is classified.
Store the bottle at 15 to 25 °C, tightly closed in its original container, dry and out of the light. Opened or broken capsules should be handled with the irritant classification in mind.
One milligram in a blended fill
A milligram is a small amount to spread evenly through a capsule’s worth of filler, and once SLU-PP-332 is blended with cellulose it can no longer be weighed or examined on its own. How closely each capsule matches the label depends on how well the powder was mixed and how it behaved as the capsules were filled. Jakubowska and Ciepluch reviewed this problem for tablets, describing how powder blends separate during transfer from bulk containers, discharge from feed hoppers and die filling, and how that separation produces units that fail content uniformity1. Their review concerned tablet presses, and how far each mechanism carries over to capsule filling depends on the equipment. For experiments where the exact amount per unit matters, that uncertainty belongs in the record.
What the research covers
What the receptors do
The three ERRs are nuclear receptors with no known natural ligand, which is why they are called orphans2. Despite the name, they do not bind estrogen. Giguère’s 2008 review described their activity as unusually sensitive to coregulator proteins, singling out the PGC-1 coactivators as working through ERRα and ERRγ2. As transcription factors the ERRs control gene networks for fat and glucose metabolism and for mitochondrial biogenesis and function2. A 2015 review placed them at a strategic node of energy metabolism in liver and skeletal muscle, and weighed their promise and pitfalls as drug targets3.
The discovery paper
Billon and colleagues reported SLU-PP-332 in 2023 as a pan-agonist of all three ERRs with its highest potency at ERRα, a subtype for which agonists had proved hard to design4. They judged its pharmacokinetics good enough for use as an in vivo chemical tool4. In a skeletal muscle cell line it increased mitochondrial function and cellular respiration4. In mice it raised the share of type IIa oxidative muscle fibres and switched on an ERRα-specific gene program resembling an acute aerobic exercise response, and the endurance effect the authors recorded depended on ERRα activation4. On that basis they proposed ERRα agonists as candidate exercise mimetics4.
What is not established
All of this is cell and mouse work, and the only primary paper cited here is the discovery study. No human study of SLU-PP-332 has been published, long-term toxicity, carcinogenicity and reproductive studies have not been reported, and none of the work used capsules. The SLU-PP-332 research guide covers the later mouse studies, including a 2024 heart-failure model in which SLU-PP-332 was tested with a related compound, SLU-PP-915. Other compounds sold under the exercise-mimetic label work through different receptors; GW501516, for example, acts on PPAR-delta, as the cardarine (GW501516) guide explains.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release. Published certificates are listed on the results page and can be checked by number and key on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Is SLU-PP-332 a peptide?
No. It is a small aromatic molecule, an acyl hydrazone joining a hydroxybenzamide to a naphthalene ring, with no amino acids in it. It turns up in peptide catalogues because peptide suppliers sell it, but its targets are nuclear receptors, the ERRs, and not any peptide receptor.
Why is it described as an exercise mimetic?
Because its discovery paper found that in mice it switched on a gene program resembling the response to a bout of aerobic exercise. The phrase describes a research hypothesis about ERRα agonists. It is not a demonstrated effect in people, and no human study of SLU-PP-332 exists.
How should the bottle be stored and handled?
Closed in the original container at room temperature, 15 to 25 °C, dry and away from light. No refrigeration is needed. The safety data sheet lists the compound as a skin and eye irritant, which matters mainly when capsules are opened or broken.
Can SLU-PP-332 be used in people?
No. No clinical study of it exists, and it is neither an approved drug nor a dietary supplement anywhere. The capsules are a laboratory reagent sold for research only, and they must not be eaten by or given to people or animals.
References
- Jakubowska E, Ciepluch N. Blend Segregation in Tablets Manufacturing and Its Effect on Drug Content Uniformity-A Review. Pharmaceutics. 2021;13(11). DOI · PubMed
- Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008;29(6):677-96. DOI · PubMed
- Audet-Walsh É, Giguére V. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacol Sin. 2015;36(1):51-61. DOI · PubMed
- Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756-771. DOI · PubMed
Research use only
For laboratory research use only. SLU-PP-332 (1000mcg) (30 Capsules) is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.